Pioglitazone alleviates the mitochondrial apoptotic pathway and mito-oxidative damage in the d-galactose-induced mouse model

Clinical and Experimental Pharmacology and Physiology

Volumn 40, Issue 9, 2013, Pages 644-651

  Prakash, Atish ^a,b   Kumar, Anil ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PANJAB UNIVERSITY   (India)

Author keywords

Caspase 3; d galactose; Mitochondria; Neuroprotection; Senescence

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; ACETYLCHOLINESTERASE; CASPASE 3; CYTOCHROME C OXIDASE; GALACTOSE; GLUTATHIONE TRANSFERASE; MALONALDEHYDE; MITOCHONDRIAL ENZYME; NITRITE; PIOGLITAZONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE (UBIQUINONE); SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BRAIN TISSUE; CELL DAMAGE; COGNITIVE DEFECT; COLORIMETRY; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVITY; HIPPOCAMPUS; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS;

CASPASE-3; D-GALACTOSE; MITOCHONDRIA; NEUROPROTECTION; SENESCENCE;

ACETYLCHOLINESTERASE; AGING; ANIMALS; ANTIOXIDANTS; APOPTOSIS; BEHAVIOR, ANIMAL; BRAIN; CASPASE 3; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; GALACTOSE; MALE; MEMORY; MEMORY DISORDERS; MICE; MITOCHONDRIA; OXIDATION-REDUCTION; OXIDATIVE STRESS; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 84883026047     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12144     Document Type: Article

References (45)

1. Harman D. Aging: Overview. Ann. N. Y. Acad. Sci. 2001; 928: 1-21.
2. Crivello NA, Rosenberg IH, Dallal GE, Bielinski D, Joseph JA. Age-related changes in neutral sphingomyelin-specific phospholipase c activity in striatum, hippocampus, and frontal cortex: Implication for sensitivity to stress and inflammation. Neurochem. Int. 2005; 47: 573-9.
3. Navarro A, Del Pino MJS, Gomez C, Peralta JL, Boveris A. Behavioral dysfunction, brain oxidative stress, and impaired mitochondrial electron transfer in aging mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002; 282: R985-92.
4. Crompton M. Mitochondrial intermembrane junctional complexes and their role in cell death. J. Physiol. (London) 2000; 529: 11-21.
5. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-12.
6. Lei M, Sul Y, Hua XD et al. Chronic systemic injection of d-galactose impairs the septohippocampal cholinergic system in rats. Neuroreport 2008; 19: 1611-5.
7. Kumar A, Dogra S, Prakash A. Effect of carvedilol on behavioral, mitochondrial dysfunction, and oxidative damage against d-galactose induced senescence in mice. Naunyn Schmiedebergs Arch. Pharmacol. 2009; 380: 431-41.
8. Inestrosa NC, Godoy JA, Quintanilla RA, Koenig CS, Bronfman M. Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: Role of wnt signaling. Exp. Cell Res. 2005; 304: 91-104.
9. Berger J, Moller DE. The mechanisms of action of PPARS. Annu. Rev. Med. 2002; 53: 409-35.
10. Kainu T, Wikstrom AC, Gustafsson JA, Peltohuikko M. Localization of the peroxisome proliferator-activated receptor in the brain. Neuroreport 1994; 5: 2481-5.
11. Fuenzalida K, Quintanilla R, Ramos P et al. Peroxisome proliferator-activated receptor gamma up-regulates the bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J. Biol. Chem. 2007; 282: 37006-15.
12. Culman J, Zhao Y, Gohlke P, Herdegen T. PPAR-gamma: Therapeutic target for ischemic stroke. Trends Pharmacol. Sci. 2007; 28: 244-9.
13. Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB. Protection by pioglitazone in the mptp model of Parkinson's disease correlates with i kappa b alpha induction and block of nf kappa b and inos activation. J. Neurochem. 2004; 88: 494-501.
14. Ponce-Lopez T, Liy-Salmeron G, Hong E, Meneses A. Lithium, phenserine, memantine and pioglitazone reverse memory deficit and restore phospho-GSK3β decreased in hippocampus in intracerebroventricular streptozotocin induced memory deficit model. Brain Res. 2011; 1426: 73-85.
15. Sharma B, Singh N. Behavioral and biochemical investigations to explore pharmacological potential of PPAR-gamma agonists in vascular dementia of diabetic rats. Pharmacol. Biochem. Behav. 2011; 100: 320-9.
16. Alleva DG, Johnson EB, Lio FM, Boehme SA, Conlon PJ, Crowe PD. Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor-gamma: Counter-regulatory activity by ifn-gamma. J. Leukoc. Biol. 2002; 71: 677-85.
17. Bernardo A, Minghetti L. Ppar-gamma agonists as regulators of microglial activation and brain inflammation. Curr. Pharm. Des. 2006; 12: 93-109.
18. Kumar A, Prakash A, Dogra S. Naringin alleviates cognitive impairment, mitochondrial dysfunction and oxidative stress induced by d-galactose in mice. Food Chem. Toxicol. 2010; 48: 626-32.
19. Wills ED. Mechanisms of lipid peroxide formation in animal tissues. Biochem. J. 1966; 99: 667-76.
20. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [N-15]-labeled nitrate in biological-fluids. Anal. Biochem. 1982; 126: 131-8.
21. Ellman GL. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 1959; 82: 70-7.
22. Kono Y. Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide-dismutase. Arch. Biochem. Biophys. 1978; 186: 189-95.
23. Luck H. Catalase. In: Bergmeyer HJ (ed). Methods of Enzymatic Analysis. Academic Press, New York; 3rd edn, 1971; vol. III; 885-93.
24. Habig WH, Jakoby WB. Assays for differentiation of glutathione-S-transferases. Meth. Enzymol. 1981; 77: 398-405.
25. Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961; 7: 88.
26. Berman SB, Hastings TG. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: Implications for Parkinson's disease. J. Neurochem. 1999; 73: 1127-37.
27. King TE, Howard RL. Preparations and properties of soluble nadh dehydrogenases from cardiac muscle. In: Ronald W. Estabrook MEP (ed). Methods Enzymol. 1967; 52: 275-94.
28. King TE. Preparation of succinate dehydrogenase and reconstitution of succinate oxidase. In: Ronald W. Estabrook MEP (ed). Methods Enzymol. 1967; 58: 322-31.
29. Liu Y, Peterson DA, Kimura H, Schubert D. Mechanism of cellular 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction. J. Neurochem. 1997; 69: 581-93.
30. Sottocasa GL, Kuylenstierna B, Ernster L, Bergstrand A. An electron-transport system associated with the outer membrane of liver mitochondria. A biochemical and morphological study. J. Cell Biol. 1967; 32: 415-38.
31. Gornall AG, Bardawill CJ, David MM. Determination of serum proteins by means of the biuret reaction. J. Biol. Chem. 1949; 177: 751-66.
32. Boatright KM, Salvesen GS. Mechanisms of caspase activation. Curr. Opin. Chem. Biol. 2003; 15: 725-31.
33. Rohn TT. The role of caspases in Alzheimer's disease; potential novel therapeutic opportunities. Apoptosis 2010; 15: 1403-9.
34. Cui X, Zuo P, Zhang Q et al. Chronic systemic d-galactose exposure induces memory loss, neurodegeneration, and oxidative damage in mice: Protective effects of r-alpha-lipoic acid. J. Neurosci. 2006; 84: 647-54.
35. Tian J, Ishibashi K, Reiser K et al. Advanced glycation endproduct-induced aging of the retinal pigment epithelium and choroid: A comprehensive transcriptional response. Proc. Nat. Acad. Sci. USA. 2005; 102: 11846-51.
36. Castellani RJ, Harris PLR, Sayre LM et al. Active glycation in neurofibrillary pathology of alzheimer disease: N-epsilon-(carboxymethyl) lysine and hexitol-lysine. Free Radic. Biol. Med. 2001; 31: 175-80.
37. Song X, Bao M, Li D, Li YM. Advanced glycation in d-galactose induced mouse aging model. Mech. Ageing Dev. 1999; 108: 239-51.
38. Kong WJ, Wang Y, Wang Q, Hu YJ, Han YC, Liu J. The relation between d-galactose injection and mitochondrial DNA 4834 bp deletion mutation. Exp. Gerontol. 2006; 41: 628-34.
39. Wallace DC. Mitochondrial defects in neurodegenerative disease. Ment. Retard. Dev. Disabil. Res. Rev. 2001; 7: 158-66.
40. Kalonia H, Kumar P, Kumar A. Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: Possible role of peroxisome proliferator activated receptor-upsilon (PPARupsilon) in Huntington's disease. Pharmacol. Biochem. Behav. 2010; 96: 115-24.
41. Miglio G, Rattazzi L, Rosa AC, Fantozzi R. PPAR-gamma stimulation promotes neurite outgrowth in SH-SY5Y human neuroblastoma cells. Neurosci. Lett. 2009; 454: 134-8.
42. Turrens JF. Superoxide production by the mitochondrial respiratory chain. Biosci. Rep. 1997; 17: 3-8.
43. Pipatpiboon N, Pratchayasakul W, Chattipakorn N, Chattipakorn SC. Ppargamma agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets. Endocrinology 2012; 153: 329-38.
44. Yi JH, Park SW, Brooks N, Lang BT, Vemuganti R. PPAR-gamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res. 2008; 1244: 164-72.
45. Gensch C, Clever YP, Werner C, Hanhoun M, Bohm M, Laufs U. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis. 2007; 192: 67-74.